Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2026 08:32 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
April 20, 2026 05:19 ET | Source: Novo Nordisk A/S

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...
April 14, 2026 02:00 ET | Source: Novo Nordisk A/S

Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered

Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcareNovo Nordisk will integrate OpenAI's most advanced AI...
April 13, 2026 06:36 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
April 09, 2026 08:28 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU

Wegovy® injection is the first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
April 07, 2026 06:46 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 7 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
March 30, 2026 07:49 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 30 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
March 27, 2026 06:23 ET | Source: Novo Nordisk A/S

Vedtægter for Novo Nordisk A/S 2026

Vedtægter for Novo Nordisk A/S 2026 Vedhæftet fil AOA260326-NN Vedtægter 2026 ...
March 27, 2026 06:23 ET | Source: Novo Nordisk A/S

Articles of Association for Novo Nordisk A/S 2026

Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026 ...
March 26, 2026 19:36 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..